BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 04 2019 - 4:15PM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the compensation committee of BioCryst’s board of directors granted
four newly-hired employees options to purchase an aggregate of
67,500 shares of BioCryst common stock on May 31, 2019, as
inducements material to each employee entering into employment with
BioCryst. The options were granted in accordance with NASDAQ
Listing Rule 5635(c)(4).
The options have an exercise price of $3.50
per share, which is equal to the closing price of BioCryst common
stock on the grant date. Each stock option vests in four equal
annual installments beginning on the one-year anniversary of its
grant date, in each case, subject to the new employee’s continued
service with the company. Each stock option has a 10 year term and
is subject to the terms and conditions of BioCryst’s Inducement
Equity Incentive Plan and a stock option agreement covering the
grant.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral
small-molecule medicines that treat rare diseases in which
significant unmet medical needs exist and an enzyme plays a key
role in the biological pathway of the disease. BioCryst has several
ongoing development programs including BCX7353, an oral treatment
for hereditary angioedema, BCX9930, an oral Factor D inhibitor for
the treatment of complement-mediated diseases, galidesivir, a
potential treatment for Marburg virus disease and Yellow Fever, and
a preclinical program to develop oral ALK-2 inhibitors for the
treatment of fibrodysplasia ossificans progressiva. RAPIVAB®
(peramivir injection), a viral neuraminidase inhibitor for the
treatment of influenza, is BioCryst's first approved product and
has received regulatory approval in the U.S., Canada, Australia,
Japan, Taiwan, Korea and the European Union. Post-marketing
commitments for RAPIVAB are ongoing. For more information, please
visit the Company's website at www.BioCryst.com.
BCRXW
Contact:John Bluth+1 919 859
7910jbluth@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Sep 2023 to Sep 2024